<SEC-DOCUMENT>0001193125-13-453630.txt : 20131126
<SEC-HEADER>0001193125-13-453630.hdr.sgml : 20131126
<ACCEPTANCE-DATETIME>20131126060400
ACCESSION NUMBER:		0001193125-13-453630
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20131126
FILED AS OF DATE:		20131126
DATE AS OF CHANGE:		20131126

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NOVOGEN LTD
		CENTRAL INDEX KEY:			0001075880
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-29962
		FILM NUMBER:		131242332

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 1
		STREET 2:		16 - 20  EDGEWORTH DAVID AVE
		CITY:			HORNSBY NSW
		STATE:			C3
		ZIP:			2077
		BUSINESS PHONE:		01161298780088

	MAIL ADDRESS:	
		STREET 1:		LEVEL 1
		STREET 2:		16 - 20  EDGEWORTH DAVID AVE
		CITY:			HORNSBY NSW
		STATE:			C3
		ZIP:			2077
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d636939d6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Form 6-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE 13a-16 OR 15d-16 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the month of November, 2013 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Novogen
Limited </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of registrant&#146;s name into English) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>16-20 Edgeworth David Ave, Hornsby, NSW 2077, Australia </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form 20-F&nbsp;&nbsp;<FONT
STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form 40-F&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):&nbsp;&nbsp;<FONT
STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note</B>: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted
solely to provide an attached </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">annual report to security holders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):&nbsp;&nbsp;<FONT
STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note</B>: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to
furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant&#146;s &#147;home
country&#148;), or under the rules of the home country exchange on which the registrant&#146;s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the
registrant&#146;s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant by furnishing the information contained in this form is also thereby furnishing the information to the Commission
pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;&nbsp;&nbsp;&nbsp; No&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT>
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If &#147;yes&#148; is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b) </P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Novogen Limited</B> (Registrant)</TD></TR>
<TR>
<TD HEIGHT="16"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><U>Andrew Bursill</U></TD></TR>
<TR>
<TD HEIGHT="16"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Andrew Bursill</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Company Secretary</TD></TR>
<TR>
<TD HEIGHT="16"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date 26 November 2013</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="31%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOVOGEN LIMITED</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(NASDAQ: NVGN)</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">


<IMG SRC="g636939tx_pg003.jpg" ALT="LOGO">
</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>MARKET RELEASE </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">26&nbsp;November 2013 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Novogen files suite of patents for
anti-tropomyosin drug technology </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>26&nbsp;November 2013, Sydney, Australia</B>: Novogen Limited (<B>ASX: symbol NRT; Nasdaq: symbol NVGN</B>) today
announced the filing of a family of provisional patents in the US covering anti-tropomyosin (ATM) drug technology. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ATM drugs represent an entirely novel
approach to anti-cancer therapy, blocking the ability of cancer cells to divide and doing so in a highly cancer-specific way. Based on their action, ATMs belong to a class of anti-cancer drug known as anti-mitotics. Current anti-mitotic drugs are
taxanes and vinca alkaloids and remain among the most widely prescribed anti-cancer drugs after 40 years of use. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr Graham Kelly, Novogen CEO, said
today, &#147;filing these patents represents a critical step for the Company in protecting such a potentially valuable piece of intellectual property. Taxanes continue to dominate anti-cancer therapy even though they recently came off-patent. We
believe that ATM drugs have the ability to replace taxanes and to become the next generation of anti-mitotic drugs.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tropomyosin is a protein found
in actin filaments, a key component of the cytoskeleton of a cell. Actin filaments provide a cell with the ability to contract. One of the ways that contraction serves a cell is during cell division when separation of the two daughter cells occurs
by the formation of a ring known as the contraction ring. When that ring tightens, the two cells effectively separate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ATM drugs target a particular
isoform of tropomyosin known as Tm5NM1 on which cancer cells are highly dependent. Targeting this particular tropomyosin isoform prevents formation of the contraction ring and hence the ability of the cancer cells to divide. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;The current generation of anti-mitotic drugs, despite their widespread use, comes with two key negatives. The first of those is a serious side-effect
profile. The second is that many types of cancer are inherently insensitive to them. ATM drugs to date are showing an apparent lack of serious toxicity as well as an ability to kill cancer cells that are insensitive to taxanes.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Novogen is focusing its ATM drug development program on prostate cancer, melanoma and children&#146;s cancers where it would be used as a monotherapy, as well
as adjuvant therapy in combination with the Company&#146;s super-benzopyran drug technology in order to provide comprehensive assault on the full hierarchy of cells within tumors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">NOVOGEN LTD &#150; ACN 063 259 754 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16-20 Edgeworth David Ave, Hornsby, NSW, 2077 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">P: +61 (0)&nbsp;2 9476 0344 - F: +61 (0)&nbsp;2 9476 0388 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">www.novogen.com </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Novogen </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Novogen Ltd is a public Australian biotechnology company whose shares trade on both the Australian Stock Exchange (symbol &#145;NRT&#146;) and NASDAQ (symbol
&#145;NVGN&#146;). The Company is based in Sydney, Australia and is focused on the development of novel anti-cancer drugs based on two proprietary drug technologies - the super-benzopyran chemical family and anti-tropomyosin drug technology. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Tm5NM1 </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tm5NM1 is one of approximately 40 different
isoforms of the protein, tropomyosin, that occur naturally in the human body. Tropomyosins combine with the protein, actin, to form actin filaments, making up part of the cell&#146;s cytoskeleton. Human cancer cells have been shown to be highly
dependent on Tm5NM1 for their survival and ability to divide. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Super-Benzopyrans (SBPs) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SBPs are small molecules constructed around a simple benzopyran scaffold. Members of this family of drugs are showing high potency against both cancer stem
cells and somatic cancer cells recovered from both ovarian cancers and glioblastoma cancers. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contact details </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr Graham Kelly, Chief Executive Officer </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tel: 61 2 9476 0344
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Fax: 61 2 9476 0388 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mobile: (61)&nbsp;0429 854 390 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">16-20 Edgeworth David Ave Hornsby NSW 2077 AUSTRALIA </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">PO Box
2333 Hornsby Westfield NSW 1635 AUSTRALIA </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Email: graham.kelly@novogen.com </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Web: www.novogen.com </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g636939tx_pg003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g636939tx_pg003.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`4P#N`P$1``(1`0,1`?_$`-8``0`"`@(#`0$`````
M```````("0<*!`4"`P8!"P$!``$$`P$!``````````````$%!@<(`@0)`PH0
M```&`0,"`P0$!`X3``````$"`P0%!@<`$0@2"2$Q$R(4%19!,B,74=$E&&%Q
MD:%"8I+2,T,D)QD*\+%2@E1T529VUC>7.%B8J%EI&A$``0,"!`(%!@@)!PT!
M`````0`"`Q$$(3$%!D$246$B$P=Q@3)"%`B1T5*"(S,5%J%B<M)#4Y,D%Y*C
MTS0E51CPHN)C<X-4E*1%9:569__:``P#`0`"$0,1`#\`W[WCQI',W4@_<H,F
M+%LN\>O'2I$&S1HV2,NY<N%U3%31001(8QSF$"E*`B([:@D-!<XT:%](HI)Y
M6PPM+IGN#6@"I))H`!Q).`"T*N7W>\YKY$Y)94G>,N?YG$N`8VP+5?&%9AZG
MCR7)+5ZM'4C#7F0D++5)R24>75\BJ^3("X)(LU$"%*`@81U2W?XP:\=<FAV]
M*(M,B<6-[+7%W+@75(.!.(RPP7JMX:^Z5X?Q;-LG;ULA<[D?$'SN,DS:.?VN
M2C'M`$8(9E4EI)S4;0[PG=)'I,/,NYEV-N8OR#AS82_@_P!GH^>K9_BYOKE_
MK?\`-Q_F*^_\*/@F:'[);0']=<8C]JK[NQ1W3<R<B<EY.XQ<LLF+9$R))L#Y
M*PE<)6'K%??2<'$HH,KU0%D*S$PC%Z\A.M"49CZ`K&:'==9A!(NLU^%&_P"[
MW,)M,UJ0.U.,!S#0#G;CS4``%1@:=%>A:A^]+X!:'X?6-KNG9-J8-%[PQ7#`
MZ1X:74[J2KW.+16K#TDLZUM!:S2M)DT1-$31$T1-$31$T1-$31$T1-$31$T1
M-$31$T1-$31$T1-$31$T1-$31$T1:_']8+YN#@/C*WXU42:.SRWR@0?P,BM&
MOA;RU2PU'G1+>I[[$P+MSVGK)!-C>`&*[<F+XI:Q7XL[K^[NW3:6SJ:C>58W
M'%K/7=TXCLCRGH6VGND^%IWIOC[TZC'S:'I!#@"*B2Y<#W8Q_5#Z4]#A'TK1
MX1;I-$"I(E`J94DTBI%\DDTR@4A0#Z`*4-M:9DDU<[$_&O6]D;88^5N5`*=%
M%YAX@&I9B*G-2OM\7Y1O&#,HX[S=C*0-&9"Q/;(NZ59P)C@V=.XM8#.X61(F
M8@N8BP1QE63M(1Z56ZYBCX:K.@:W<[?U>'5K,TEB>#U$<0>HBH*M?>6U],WC
MMV[V_JT8DLKF!\;AU.%*@\'#-I%"'`$9+^FQQ>Y#T7E=@+%W(''#L'%7R75F
M$ZBV.8@O(63,46T[7)1,ISBWE:],H+LW"9O$%$1^@0'6^VE:E;:OIT.I6AK;
MS,#AU5S!ZP<#UA>%F]=J:ALC=-[M;4Q^\VD[F<W![,V/&6#V$.ZJTS"SYJH*
MUDT1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31%JY
M_P!9!X5EL^/Z;SLI$7UV/#S9IC_-)D3*'5?8EG)8"UJ?!#VBB:DW*5Z5A*`#
M[G)J'-[*.L)^-.UWZKHK-;M16XM,'#IC<0*_-/X#U+>#W,O$V+0MPS[!U)P;
M;7Y,MN?]<UOTD=<J/C;S##..E>T`M0`#='0H`=8.P#H-Y_1OX[>`!L.M2N)`
MX+U$#J`.&(DR7Z`;>'TAY_IZYMP%.*E<R*AK#9IF!J50AG5BMUPG8FJ5*`8I
M*+OYJRV!\C&0L8U02*9115T^<$+X`.Q=Q\@'7<TW3[C5+Z+3K5I=-,\-:.LF
MBI>LZK::)I4^J7SV1V<$;GO>XT#6M%2XDX```DK?#KUVQWV2^%7&K`?RJ[RY
MDB:4D%K!"UZ;:5U:P6V2Z[+E7("SZ31DD&4*SL,JFV;)^F`K$42*78Q3Z]%_
M#_8LC=*BT:T>&Q6T8#GD$@O)J:8^6F.``Z5^>#WF?>%TV#>4^[;Z!\S]0N'"
M"%KFL<RWB'*U[B1F>S@1BYSJ'LK'_P#3K,/^4VW_`.]:K_ZN:R)_#FX_XN+^
M0[XUK#_BIT3^Z;G]LS\Q92PAWG*)E/+]"Q?<,)V'%49?Y<M;C[S)WJ#L,5'V
M5^4$Z]&R;!C#L7#=O.2`E:E<^IT(K*$ZPZ3"8.C?;"U"SM9+IDC)!&VM`""X
M#.F?"IZ\E7=M^\CMS7M9M]*N+.:TCGD#.]?(PL878-+L&X%U&DUPK7(*ZG5B
M+8]-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$7RE[H]
M6R92K9CN\0[2P4Z\5V8JEHA'R8*M)6"GF"\;)L5R&`?97:.#%W#VBB("`@(`
M.OG-%'/$Z"9H=$]I:X'(@BA!\H7?TK4[[1=2M]7TV0Q:A;3,EC<,VO80YI^$
M8CB,"OYLG+'@SG'B9R/R?@8N-\G7.N5*<5<8[NL%0K78(BV8WF1,_I\HE)0\
M9(,ADFL<I[B_3%7U$WK17<-A*(Z4[O\`#W6](UV>VTZUGGL><F-S&.<.4X@&
M@.(K0^0KVG\+/&?:V]-FV6N7%[;6]^^,-FC?(QICE:`'MH3@*U+>EA:>*CP7
M$69A(8WW*YGZP'ZOW49`W-^B`?+P>&K9&TMT`T^S[SF_V3_B60QOG9_(7?:=
ME4']='C_`)RV`.P!P7F[#G*Y<R,YTFR4FC\=6KN(QDVR!6Y6KDE\D2T4LK8K
MFDUL+-BL>-QY5E!(FXZ/3]\D>LANIN.LZ^#6P=0MM1?KNL6\D<[0&0,>TAQ<
MZH+J''`4`PS=U+27WQ/&S2(=K-V9H-W"\759+J1CP6Q6\7:+7$'#O#G7`L8[
MI75<N>1+_E1R%NN7#KKFIR;@]/Q0P7*<A6&/H1RLFP>@@81!-W:'AU9%<?/[
M<A/(@:]$-NZ3#IFG1V[""_EK(1Q><3\&0Z@OS.^)V\9]Z[MNM7)=[)S\D+3Z
ML+,&##"IQ>ZGK/.>9COT_MA_7_'JLTCZ%CW%<5ZU!=JJ0BJJ+DHIKM':)A37
M9/&YRK-'C=0H@9-=HX3*H0P"`@<H"`[AJ'1MN"`\D1-S'25SCE=#('MS6X5V
M\>4:?*7CK79^9=I*9-HOH4/*K0!`JHVF(9H`E8`2_8L[?&BE()"'L@951,/%
M,P!@/<VEC3-4>V($6LA+F=0)Q;\TX>2B]+O!_>S-Z[/AFF<#JUHUL,XXDM'8
MD_WC1S'\8.'!3JU;RRHFB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:
M(FB)HB:(FB*FSF]W3Y7C3FPF&,7XWK63'\%7&<I?Y::LKR);5^<F#BXBJTU)
M&M7AEWZ<.4KIUZ@E],KE(H!OU;7[MC9S=<MG7%R^2,9MI3$=/:&-36E.`6M'
MBIX\W>R-Q?8.AV]I<F)C>^=*9#21V/(T1D`<K>4N+C6KJ4%*F(P=\+-._M<=
M\=;;;[A>;#L`_@'\DCJO#P[L:"LT_-\SXEC,^]+NSAI^F?\`4?GKM'?//+_/
MW#_(3C1$5N%P[EJ:QJK:\=?*\\^EPRA7ZR]1>Y+QHDX?-6;N'L,Y6@$C4Z(G
M]9$ZQ3=``(C\#MZQVS?V^I-[R6%K^5W/3L%V#']D`4:[`URJ",E4X_%K<7BM
MM[4]J!EO9ZP^V[V(0AY]H9%5UQ;'G<2'R1XLY:5#7,/I!4AQSANX8M%&B8IM
MO2*5)$Y/341Z`Z#(G3$`%,Z)BB4Q1`!*("`^6LC-H8P6X$T)`X+4V1KFR$/]
M*JYNN:X+\'I$HAN`"(#M^`1#Z/UM*/H2`:`CX$KCBK">W_F&Q<6:YR,Y8NO>
M9#&4+$UO%+/&R3M*--F'-4K)M7U>CH>0<HN4(]2EP*[E=\[(DL<C5P8HE$";
M!9N[[6#6+J#3HB&O-7EP%>5H%"3EZ1HT#B<?5QSWX.ZY>[#M=0WK<DG2(XVP
M=T7<OM$\C@YD;<#C$P/E>^A+&T;2DA(F(/?5GP`1-Q.'PVWZ<QM!#?8-P`?D
M0/(1U0/X<3\[6"Y;B*^A_I+*?^*FRI7[)?G^N']&N8P[ZRR<K#!9>+SJ'K*T
MI&HV.;995:2KN"@G#Q%&5F6\5\EM!E5(IF<Z_NX*I"J"8E`P"(:Z\WAY?16Y
MN!*TM!RI^'/)?:#WIM,EG$4FF2-82*TE!-.-!R"II6@XF@ZU?]$2T=/1,9.0
M[Q"0B)F/92T6_;'!1L^CI%LD\9/&ZA=RJ(.6RQ3D,'@)3`.L?2,=&\QO%'M)
M!\HP*VIM+J"^M8KVV<'6TT;7L(XM>`YI\X(*Q[FC-F*^.^.+!ES--SC,?XXJ
MP,1G[7,)OE6$;\3D&T6P!5*-:/GJAG4@\22*":1QZCAOX;CK@NPO5A/.F(N1
MV/(G*^#[[!9(Q[.+R+2-L]?57.S5>1+Q6/DF:R#M!J^9/&;M$Q3HKI)J`&QN
MGI,41(N!F/D-A?C\&/!S)D"'H097R'!8GQW\73D5/FG(EF*Y/!5:/^'LGO0_
MD2,U1(9;TT0`@]1RZ5HBS(HHFBF=54Y$DDB&4444,4B::9"B8YSG,(%(0A0$
M1$1V`-$5;.3N\'VT\06U_1KMRYQHG9XE0Z$K'U@EDOJ,:X25.@LU?2E$@;'$
M-7B*J8@=$ZX*DV]HH>&HJ%%5*#CORVXU\L:VK:^.F9Z-EB(;;_$"5F5`9F($
M%/2`)RM2";&R00G4\">^-$>O<!+N`@.I4KN,6\D\'9INN7L<XPR)#VN]X$L[
M6FY?JK5"493-%L;UNLZ91\LUE6#`RA7C9`RB2[<5FZA`W*H.X:(LXZ(L+0O(
MG"MCSE<N-<#D&'ELXX\J$'?+QCUBE(N)6JU2RKE0@)2:>$8C#LC2YS@9!N9R
M#HZ?V@)]'M:=2+"W(SN*<)>)LLVKN?\`D;CR@VAW_!U(SU]9+<F7H%0JKVK5
M)C/3T:W.7ZJKENBF81``,.X:BH"576\>.Y7P5Y66-2FX'Y*X]NUR()03J"J\
MI5;0^$4Q5$(>!N497Y.<]-,!$XLDEP3V]K;2H454Y-2I4(.0/<FX*\6I_P"4
M\Z\FL:4>VE4!)Q4PD'MFM,><0,8`EJ[4&$_,0X"!!V%TBB`CY>8:51<+C[W-
M>!G*:YML<X'Y.8XO>07P/3QE'(XEJ[;9A.-8.)215A*_;(N"E)I*/C6JJZYF
MB2P(I)F,?I`-]0""F:[?/W<6X3<6KR7&O('D+2\87D\$PLQ:[/M[$H\^!2:S
MINPD14BX20:%1=+,E2E`5`/[`[@`;:$@9HL5T[O"=M#(%TIV.Z;R]QG/W7(%
MHA*53:\R0M8/9^TV-^C&0D,S%>N(MRNI%^X(D05#D)U&#<P!XZ5"BH4@,T\W
M>*7'3(U(Q+F[-M1QOD/(Z$>ZI=;L02R2TVVE9WY98.4WS:,<Q3)NO.?R?K<K
MHD(;Q,(%`3:E352IT182K/(["%QS)DSC[6<B0LOF7#L;4IC)E!;IR)9BHQEZ
M237J3N0478I1ZJ<TDJ44_065$O4'6!=PTJBZ?E1R`@>,."+]F2=3(\/6HL$:
M["F/T*6*W2RQ(VL0*/3[8_$)=RF"IB[BFW*HIY$'54T;37ZMJ$=DS!IQ<>AH
MQ/GX#K(5F[_W;!LG:MUK\H#IHVAL3/ERO/*P>0'M.X\C74J:!:4DA+6"TSMA
MN%NDEIBUW.=E;99I5R<ZBSV;G'1WKTW6<QC^@B90$D2[[)HID('@`:V#L[=E
MI9L8S!X`%!P`P`\R\NM4U&XU34);^Z<7SRO<YSCZSG$EQ/E)JN.&VW@'A_9Y
MZ[+B:XYKHTHN[JMRM6-;C4LET-^,7=<?S["T5IX'U1>QRG4K'NB?57C9AF*C
M1TD;<JJ"QRB`@.NI?6S+ZRDLW"KI!2G4<_\`+@JMH6L7N@:O;ZQ8/Y+JWE:]
MIZ'--17I!R(X@D'`J0_+BDUQE<JIR#QNBDVPIRPB'.3:<S3*FDE3K^F9)/*F
M-ETD2)I-7$%8U3N$DP``%-<X%W!,=J/H5Z.Z.DW5?M&!W(\GU@/JWC\IN?6"
MKV\1=%A%S!NW1XVLV_J[#-$UN4,N'M-N1P[F4GERK&YA``46^L/[M']V&K@[
MO\5WPK&>/6N7%PL];)VN4NJ1II:VW.?B:I58QM[2C^>G7B;%@EMYE1(JKUJF
M'P(D0QA\`U\YG&TC=<]Z&1!A)#CD`"3^!=[3-/N=5OHM/LXW27<TC6,:!BYS
MB&M:/*2`I-\K;#7(R?I/&''3LCG&G%*.?5*2E&@^FTR#G>4.1;+V0%TRE`'!
MTILJD<U4,)Q*FFH!3=(@`4'1+8@'49Q^\7G;%?5C_1L\S>TX?*<>A9`\1-1A
MMGV^S-->':9I##$YPP$MTXUNI\,"'2#NXSGW4;<JFL7-7(#CBL8KTG*0Z9TU
MRE.4PB42"&X"0P;"`@/F&PZ^@;25S6_5/;0J*G!P](+9`[-?)EQ=\9SW&JX2
MBCRW8:3+)4AP[5.HYEL32CH$8]KZJFYEEJ9+J&8F#<1(T5:AMMXCAC?&BFQO
M!>1#Z%]`[\K&A\X'PCK6]7NX;[;J^C/VA>./MMF"^$GC"3VF#&M8WFH%/1>*
M>B5]9WXG)F?:XY(NR``J-DL?KI]0`8.M+(U6.7<!W`0W+Y>0ZL(Y+9LJ*?".
M67X(<[8_CM(I(PG&ON,XGJO(3CLDF)&5<I>?J]2X,V6\:1+;K!JQ&SL'*;]N
MD4`,H)&Y``3B(F5Q\J@88+,O>U*4R?;:ZB@;;N28&$-P`=A"/M?B&_D.AS"Y
M')>/=>NV0<ZYHXH=KS%-TGL>FY6R=DN7(.\5-ZFRLT+QTQ^S7<66`B7/K)+-
M7-T<)JHF,40$Z34R8B)#G(8<<%!Z%9E@WAOQ>XX4.+QQAO!F-:;6HQ@R8*`S
MJ$&K+39F38&Q9&S3;ABI*6*67+N95R[554.8QO$`';4T4JE_NF\5:SP@DJ=W
M6.'=<B</Y`P1<:J7D)2Z(P:5BE9DPW:;)'0%E0L5>B?A\6>525E$R'4*G]N5
M8%C!ZZ":FH.&*C+%?60L[$X"[UF-<L5\Y4L/]U;C!'$;O$_3+'??!BF":6*!
M5$6Z(IJOINEI(E*<3"=95X<1$")AIQ3BK\;-8X:GURP6VQOT(JO5:$E;'/2C
MHX)M8V&A&"\G*/W*@^!$&;%J=0X_04HCJ5*U5<5<@,EX&[='-#NA,X<R_)CN
M,<B%HGC\HNT26>Q54L5B^Z/CNS1,OZJGN$#%)O95H@8RC4RADC`'I*#MQX$\
M2HX*XK@/VS<(<4,;P\[<:E!Y:Y179DC:,Z9_R+%-+?D2W9`GD"/;*5"Q6!%_
M)1T(T?+G;H(HG3]1),IU>HXCM("475]Q#MF82Y78CLL[2Z77,8\G:+&N;?A/
M-E#C&=/NT'>JXB:3@6<A/0*<<^D(>0=M2H'*NH<6HG!9$2')XB*H0J[9ONJ9
MFLW9;HN:JTY08\OLJWJ,X:QDLW41;+1F;7UA<4V0OA&RZ)4T)$D"U^+>F4!(
MU>N2#XD3$-*U"')6;<)NU[QFXD8Y@F[S'=3REG25:%F<L9WR-`1=QR)>+U+@
M#ZS2AK#/MY%_'QRTHJ<J#=!0H>B0@J"HIU',`H*(`ICLN.V`8R_P^5HS".)8
MW)U>;23."R''8[J3&ZQ#28:J,95M'6=I$HS+1"29*F27*18`53,)3;@(AJ5-
M`J:YZO05H_K!_P`(LE>A;)$&X`IN56,]$,)E@5PE=UB(K^[2#=R@58I5#%`_
M3U;&$-]A'4<5''%77,\,X?CGK.2C\48U82,<Z0?1[]G1:NU>L7K90%6SQFZ0
MBR+M73=4H&(H0Q3D,&X"`ZE30+7W[EN!ZWRG[JV".-EF;L!:Y?X`\AX2(EW;
M<J[BIV^+>V.<IMOBU-O5:R,!8F""H'3$IQ2]0H"'5N$<:+B<^M6#]H_DQ<<[
M<9%<;YH%PTY,\3K;)\<.0<7(J%-*K6NB`#.$MRQ-@.=I<JXF@X(N.X+N$UQ`
M?#P#)2%&;BT4H=[GND&`I0,.+^(6X[!N/Y*@]MQVW';3BG&BR=WJ\472Z<?*
M1DFNR#U:LX3NZEGOU50!0[>2@[`Q3K;>TJI)@855:2[=>KL8.DC5VX4'Q3`=
M7SL2\AM]3=!(.W*WLG\FI(\XQ^;\&N?O*Z-?W^SH-3MG'V2RN*RMQREI&Q_1
MV74;CPDP.8.M690KDR/HAL`)>!P$!*;P\P$/#80_5UF6"-T372N-8W&H\BT'
M.&!P<%Y!Y!^AX?J>&I*+UK*$23.LIL!$B&4.81V`I2@)C"(CX```&C96Q2"H
MQ=A7HZU/*7]D=*LAK+G&O'S@IC5ER5Q./()3D9EU]F/#^"INUR5%;XTIT3$?
M"W>0R6"$3&R1IK9[VDN9H4?=7?O:0](&*J)K!F@U+4MQ31:7-W4L#.1\H:'<
MQ)#N3'#L8XY@DC(K9'2[S0-E^&UG]]++[3.IW3KFWM72.C$,3&&(S\S>VTSD
M@<M.1X:UU`YJQ+]^?"?_`,:]7_ZD<J?O==_[)W-_><G[)JH'\0/"K_X^'_G)
M_B6;..7('B*WS54XFI\1X'C1=+FRLF/J)G]KEJWY"/B^[7>">U^L3AZ[;4QB
M")K2KQ-O[YN"C45@,`@43CJFW^B;D-N^6ZN#<6D='F,M:TR-:07-J,<0#AQR
MXJY-J[[\.+G68K/2M#BT?5)P^**\%Q)+[-++&Z..7D>.4T>X`NS97G&+0JW)
MBIV'']FM./;FV59W>AV.9JUP17.HJNM8(QZJC(R*BRHBHY3EE?Y4FL(CZR:Q
M3[CU;ZO?3YXI[)DD)YHWM#@>HBHIT+7S6]/O=*U:XT_46N9>0RO8\',/82UP
MZ\1GQ!KQ7$UVL\%2UX@([E6'ZI0$!*/F(^.W]O0AKHS:CZX\5&6/!3Z[7F-\
M@Y!YHT>R4*:=UF(Q-&25KR9+MTBK(OZG,(+0C:C+IJ![NH>X2!@$`-N=%)FH
MN0.I,!U9V];R&VT=UG<T=*[!O6>'\FE?@"SCX!:+K&I[]M[S3'.CM[4F2:09
M"(`@L-<^]KW=,<"3ZM1;)W\0W[5?)[_$*./Z7\X-8UA(@D8+T3<:#SKB<YN)
MEFY2=N'$4CB94T5R1X]4;$>?>.UD:`9.699!H%1A992`8ND0]=-.XQ395B9,
M-R*+F1ZP,4NVH.(4]?%00Y?\L:WS=XH]H?D+7DBL'UH[A.!HZ]5T!V<T_(\`
MRM41=ZN\2$1.W5C)Q!04RF]H6ZB1OV6E:XA16H4E>2RQ,8]^;@9D.U*ILJGF
M'CAEC"U7DW`*`V+?HY><EF\,57H,F20F"3C9-$@B`J=0[>0Z<5/%7X:E2JC.
M^K;HBK]KCD\PD%4!D[[$4W'E2C5`$Z\Y:[1D"KHQL5'HE`5%Y`Z#=99,I0$?
ML1'Z-0<D*B;W.\*W?&/:_P")F=(`J@9H[<ZW''+S5=HBO[THTJL16:=D:)(E
MUI.!;.V;D%'"0_PJ;44S;%,;0Y=:XFM%FKNM<DUK_P`"L2XVPC*D^?NY?8L4
MX#Q2LT<E75;UO,[5E*7B:*JS!;U4(:AJN4G!D3@HF+CK((B381R4G)8X[SF+
MX/!';HXX-JI%+I8WXF\AN)<Q+LHB.%4&6/Z#/,J\[DE46B::20(@JDHH<Q2@
M=93Q]HP;CDBOIKEAA[;7H*U5Y\WE(&R0\;/0LDT537;/XF79HOX]XW62.=)5
M%RT<$.4Q3"`@/@.I4KUVB>BJM6;%9YUXVCH2N04O.S$@]6(W9L8N(CW$A(/'
M:Z@@FBV;-&YSJ',.Q2E$1T1:0%6)+5/M+\5.3LK#'0Q]7N[K(Y_D%%TCG3;8
MWL-NG*XA.'3234`(QM(HJ$,<0Z=BE$/K%WX\*KCP6\9$RL;.Q49.0SYM)P\S
M'LY6*DF2I%V<A&R+9-XQ?-%TQ$BS9VU6*HF<HB!BF`0UR7)06Y1<VG/''DQP
MEX]I8S-<4>7V0K717-O"SI0P8]+6X)*8))C#GB7Q[$+TZH)^D"S7H`.KJ'RU
M!.*BN-%4_P`EL(*\C.^6?%[7,69,%N3<'8RPDO>#+62F7<2Q]P?-SPIYD[-\
M(PSPKOK62`GMG3)XAMIQHG%6%X8[8\OA_+=#RJMS]Y\Y-2H\LXE%<=Y-S<G8
ML>6XCB,?1OPVVP)8%J,I'(B\!<B?J$V72(;?PVTIY4HHYY^W_P#H`X$_1OP]
MY!;_`+8.FW>`_H`/CIQ3BOG^6`'[=7<NQ#SECP4B>,_,M.%XU<MDFA!2AZYE
M,IS%P]F&;W*9LV*JFF5@Y7*`*"B@MN)C*@&F1JF2[GBWX=[3NBJ>`$'%7$-4
M#[ATBG\)A#^IU>71T!OOOMMIQ3BKR;#`0UK@9FL6*/;2T#88M_"S,6\3*LTD
M(N3:JLWS-PF;P.BX;+&*8/P#KZQ2R02MFB);(T@@]!"ZM_8VNIV4NGWS!)9S
M1N8]IR+7"A'P?!FM)'DU@V6XJ9VO6$IU431D2Z^/8\EG)RE//XTG'#A2M/0.
M<0]9S&`BI'NA`?!TT/OYAK8+;FHQ:MI[)&/`Y6U()R(](>8Y=5%Y@>(>SKS9
MFZ+G1YF.,;)*QN`J'QNQC?Y2V@=T/#APJ<(_$&!0#=XU\O'[=+]_JL\S7]IN
M15C]W(,"UU?(I!<5<(,N3&<*]0I.2)'8UK3-UD;-5C*X(BU@L8U4R;N71=/M
ME$6*EA6`C),YPV*110^P@F.J+KVJ.TNP+H6\]U(0Q@Z7.P'Q^97[X<[3;NK<
ML5I>DQ:1"QT]S(<`RWBHZ5U:&E11H/RG!<;DQG!;DCG*X933159TX#-ZAB:O
MBF+9M6L7UCK8UEHW8%$4F"THF4SYP4@`'J..G;8H::'9>Q::R!II,,7OXO<X
MU>:G$U.751=/?VYG;IW+<:DP<EA4,@CP`B@C')#&T#`!K`":>L7%81_O`_5U
M6Z#Y15EXKC/6I7C19`QSI"8NZ:B9A(JBL40.BL@<NQDUD%2@8A@\2F`!#Q#7
M![>=[7O<>5IH!\:YL>8W5;FIF9U6'D#A+'_+V.3(>_4D(+`7+9JFGT.%+/%L
MT&N+LNKD`1,HTNT-T-'3@0`GO8$3\R&U;5J\Z/J<FD2D"S=S2PG"@:35[/F.
M-0/D'H"RUNJ!N[MJVN^+5I=JD')::@*DDR-:&VUR0>%Q$WDD=QF8:DN=C#GU
MTMA-UEV+Y^T'X]7*'QD@-<#7H6).5^1!JN&\?)-FYES"*@D+U@B@`JJK'$>E
M)NBD3=15PNH8"D(4!,8P@`>(AJ8RR)\D\@I04%>E2(WR%L;!4DK;P[:O%Q?C
M)QSB4;,V(3*&472>1,C*&(`+QSZ59-R0E2!02%5!M584B:!B#X`\.X,'U]8$
MW1JIU34CRFL$56MZS7M.\YP'4`O23P5V3]S=FQ>TLY-6O:32U'::"/HXSQ[#
M<2#D]SL!DNA[N7'K+_*?@#G?!N!Z[&6O*5T9U9.LP,Q88ZK,'YXNX04L^(M.
M2HE8,Q3CV2IR^H(`<Q0*'B(:MLUI@LO*<>(H"6JF)\85:?02:SM:QY2H":;(
M.$W:#>6AJW&1TB@BZ2`$G*2+QL<I5"^R<`W#P'4HM<[/?;!Y4UWEN1GQRQ_5
M;%P]N7,7`_-)P5_D:%K#S#V3:\^D8S,K2"I[U`BC^%LT4]]^33:@`BIT)AN9
M,=XZN"XFO!7#]P?@W6>=N$FU!<6J4QKD^AV5AD?!N78`52S6-LF09%`BI=,&
MZS9RYB'A3B@]0(HF<Z8E4(8%4DQ`15<E`^D\CN]E@N%2QWF+@1CSEA-0C(D;
M"9IPUGJK45E;$&(*,D)NXU^XM_>64Q(BF1=8C=NU*)1$?3*8VP,5&*\:)PKY
MI<WL^XOY$=SD<;XZQ?@>=2N.%.&&(IQW;:ZO>V_IJ1=\S%:WAE&5@D8@P%.B
MS;]:8*EZ!%)'U4W#&J*Z/*>/(#+>-,@XMM39-Y6\BTRS4F<;JE`Y5(NSP[R&
M>"`#X@H1%X)B&#8Q3@`@("`#J5*U]NWCV_N:M7S=Q6'F/4JI%8@[?&)\LTWC
MX_B,B1-U<9`N]_N+UC$724A&G4Y@5*_C14K9J1?<$`3;E)T*$/O`KQ44*OZS
M)B.BYZQ7?\,Y-AR3U"R75I>H6B,,)2*+1DPU.V479KG35]TDF*ABKM5P*)D'
M*1%"^T4-2I5&V(Z+W9>V=&EP;C'$M*[AO$JLO7#3#[U3)<9BWD'0JJX465BZ
MA.FLB?RW,1D*4>D%4R+`0H`"1DTS%02C%1BN1D[&W=B[E[(<,YJQW1.WKQ`L
MSM,F6&L#D9GE#D?D6I(+(G>T1G(P2?RO66$V*72LX`J?4@80."I0%%1B?(F)
M5O%GXC8$MG%U[PWD:.S;X!=XY;8O3I\6<8_X=6F+5!"-6C7J)?5:S<:Z:I/$
M7>QE`>I@L;J-OO*FBIQQSCSO&]N%BGAK#E(QAW!N*]6<J-,6*6F^IXXSS3:@
MHY6-%5%^[EED8:10@F92(IB`.4$D]@1%)/H02C$*!@O%[CSN3\U>9'!G.6:N
M'-'XP8TXJ9/L-OG%9//%?O%NFF5BKRD8Z]QA8!BHBH5`Z"0)E$Q#"901$^Q=
MM,2B^_Y/X-Y\T7N>!S5XM<<\<YWJY^,<;AD&ETS3"XS.WF%;$^EI-8$'39V^
M,#5,B`%,*8IJE4,`"!BZ<:H:K(K'DCWM%).)1?=MOCBWC'$Q$MY=VER^B%%V
M$,XD&R,O(((_!/Y2X81QU5DTOXTY`+].G:48K(.7N+V<K7W?.(_*V`K$.ZP)
MBSC?F+']\M2UIC&DS%6ZU!/EK\<TJ:OY5E6ST9)(3.$OLT@ZNKZOB.84\5,[
MEWQHI'+_`(Y96X[W]`IH3(U7>1C.1`A!=URR-^E]5K1'*&(H9"0KT^V;NDS%
M#<?3$OD8=2<5*U\\)<+^Z_4:OS:N5@Q]0(;D7ESBUQ^XY8_N;;,%?D4+?-T6
MQLZ!9<DR#Q$/7KS^+Q(8\H3U@!1P];%3('K'':/B7&BVG=2N2P?E3C5@+.$I
M$S>7<147(DQ!,%XN'D[3`M)-]'QKIP5VNQ;.E2>L1HHY+ZGI[]('$1``$1WJ
M5CK&I::TLLI71L<:D``XY5Q!X*S=R^'VS=X7,=YN2PBNKJ)G(USG/:0VI=RU
M8]M0"20#6A)I2I6+1[?G"@1W'C'B#?\`T39?BU4V[PW(QO*R[>&C\5GYJMK^
M!WA4<]'A_:3_`-*L-\FN#=.0XK9]H/$JD5+#=[R!6F)Y(]*@V$0ZR!'UAT:4
M/09:1*0'*4?96(N6("4Y0(9R._LF.`]O3MSW4^K03ZX\SP,Y@VM`&%PIST``
M)'2<ADJ-NWPHTJPV1J6G>'UNRPO[AK'2!A>XW#(B7&#F>]Q:'BN#<'$`.!K4
M:ED8NFNT050`Z(=(IJ-E""FJW41,9%=JJD8`,DLV5(8ABB`"4Q1`=9N8YCH&
M$-HT!>=TS'LF<V3T@5V6B^:\-O:W'Q`H"(^7AY^/X=<S_5GQ_I''!0?2!X*W
MGM$\=G699OD#;;PV)+<=YRIM</VFA2S,KBO90LQ'S2Q>N[*<"G`M#;@4$UT#
MD5!R^$O4'IB&L;;XOQ8Q6]O'AJ8<7AW$-H6D_.K2F6!Z`MIO=TVA)KC]2GU-
M@DVM)`(98G5Y9I"YLC&G$?5\O.2,07-`-"X&X;^C+X';"'YM%!V-YAUV#QV\
M/\MZL2/<VO14[NYD'+EEA^!;+GP?\,W9Z-:?`[\Y<^'[;W!N`FH2Q1/&['[6
M8KDO'3T*\$DRY]REHAVD^CGI6[J67:K':.T"*%*H0Y.HH;@.IFW1N"X!$UU*
MX$4S''#@%];;PF\.+.=ES;:1:,F8X.::.-"#4'%Q&!%<5-S5!61$T1-$31$T
M1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$6I/W2.-`\=N2#B^
M0B*;;%_(-Y+6J&!-,$6M>R&W!%>[5SV2E020ECN"RC0H;`(++D`/L]QS7L?6
M67UD;2Y=]+&`#4YT]$^<"GE"\]O'S84FU]T.U2R9_96H.=*RF37UK+'\UQ#V
M_BO`X4%=/O*/^%(?NT_QZO/L`^BL!\IZ%SX.!G[Q9JOC^E-QE;E?[!%U*L,6
M^RIUY>9<%:HJG(01$&K%(QW"YO)-!(YA'8-?*[NA;V[KLD!D()(/0!4GS*HZ
M3IEUJVH0Z=:1NDNII&L8T#$N<0UH\Y(\U2MW#CA@ZL\<,*8_PW52$.QIL$V:
M2$D"14EI^Q.=WEDL;P`\1=SLTNNY-N(B4%`+OL4-:[ZKJ,NJZA+?39O=@.AO
MJCS#\.*]2]E[8M-G;:M=OV@%(8QSN'KRNQD?\YY-!P;0<%F_5.5TIHB:(FB)
MHB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HBKD[F_PG[B
MJQ\:_,V]R^\V`_XV/G;[N?6^&S7I_+'R!^7_`)X\_=_XCW7U_4^C5?V]S^U.
MY/:J\OZ#EYL^//AY.-5BSQ7[C[&M_:/L/N_:/^Y]]W=>1WU?<=OG^57L\N>-
M%2!_-[_Z&/\`N?U?G[S_`.=_F%KW_97_`.=?^Q4LN#7RC^=+CGX/_1`>_>YV
MOH_-Q^^[[\?2^`NO5^0OGG_-WU_+WSK^V]Q]7T_IU1=9[[V&;G^U>7E'UO=<
MF8]/EQIY.-*J]=@>P?>JT[C[D]YS.I['[9[1Z#J]SWWT?/Y<>7FIBMBC6/EM
J$FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB+__9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
